Highest-materiality recent filing
Niki BioSolutions names Thomas Freeburg CFO with $250K salary, 50,000 options at $8.83
Board appointed Thomas Freeburg, 59, as CFO on Oct 9, 2026; two-year term commencing Sept 1, 2026, reporting to CEO Ian Huen.
Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.
Niki BioSolutions files corporate presentation for H.C. Wainwright conference
Corporate presentation led by President & COO Alidad Mireskandari, Ph.D. at H.C. Wainwright Global Investment Conference, September 2026.
Niki BioSolutions names Ian Huen CEO/Chairman and Alidad Mireskandari President/COO
Ian Huen appointed CEO and Chairman effective Aug 1, 2026; 6-month initial term, HKD 210,000/month (~USD 26,800).
Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt
Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).
Niki BioSolutions posts H1 2026 net loss of $1.3M, flags going-concern doubt
H1 2026 net loss attributable to Niki was $1,326,004 vs $441,780 in H1 2025; EPS loss of $1.6.
Niki BioSolutions regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency letter on March 5, 2026 for bid price below $1.00 for 30 consecutive business days.
Aptorum completes merger with DiamiR, redomiciles as Niki BioSolutions, trades under NIKI
Merger closed July 20, 2026; Aptorum redomiciled to Delaware and renamed Niki BioSolutions, Inc.
On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.
Max materiality 0.80 · Median 0.57 · Most common event leadership